Janney Montgomery Scott LLC boosted its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 0.2% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 987,673 shares of the company’s stock after buying an additional 2,171 shares during the period. Janney Montgomery Scott LLC’s holdings in Merck & Co., Inc. were worth $59,952,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of MRK. Rockland Trust Co. bought a new stake in Merck & Co., Inc. during the second quarter worth about $3,949,000. Middleton & Co Inc MA lifted its stake in Merck & Co., Inc. by 4.0% during the first quarter. Middleton & Co Inc MA now owns 157,307 shares of the company’s stock worth $8,569,000 after purchasing an additional 6,063 shares during the last quarter. Stephens Inc. AR lifted its stake in Merck & Co., Inc. by 2.7% during the first quarter. Stephens Inc. AR now owns 365,496 shares of the company’s stock worth $19,909,000 after purchasing an additional 9,526 shares during the last quarter. Sawyer & Company Inc lifted its stake in Merck & Co., Inc. by 10.7% during the second quarter. Sawyer & Company Inc now owns 22,984 shares of the company’s stock worth $1,395,000 after purchasing an additional 2,215 shares during the last quarter. Finally, CenturyLink Investment Management Co bought a new stake in Merck & Co., Inc. during the second quarter worth about $2,648,000. 73.02% of the stock is owned by institutional investors.

Several equities research analysts have issued reports on the company. Bank of America lifted their price target on Merck & Co., Inc. from $70.00 to $74.00 and gave the stock a “buy” rating in a research note on Monday, July 30th. Zacks Investment Research lowered Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Monday, June 18th. Deutsche Bank reaffirmed a “hold” rating on shares of Merck & Co., Inc. in a research note on Wednesday, April 25th. SunTrust Banks reaffirmed a “buy” rating and set a $77.00 price target on shares of Merck & Co., Inc. in a research note on Thursday. Finally, BMO Capital Markets reaffirmed a “buy” rating on shares of Merck & Co., Inc. in a research note on Wednesday, April 25th. Six investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $66.55.

MRK opened at $69.06 on Friday. The stock has a market capitalization of $178.14 billion, a PE ratio of 17.35, a P/E/G ratio of 2.28 and a beta of 0.80. The company has a current ratio of 1.33, a quick ratio of 1.04 and a debt-to-equity ratio of 0.61. Merck & Co., Inc. has a 12 month low of $52.83 and a 12 month high of $69.24.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Friday, July 27th. The company reported $1.06 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.03 by $0.03. The firm had revenue of $10.47 billion for the quarter, compared to the consensus estimate of $10.28 billion. Merck & Co., Inc. had a return on equity of 32.68% and a net margin of 3.67%. The company’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.01 earnings per share. analysts predict that Merck & Co., Inc. will post 4.27 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 5th. Stockholders of record on Monday, September 17th will be issued a $0.48 dividend. The ex-dividend date of this dividend is Friday, September 14th. This represents a $1.92 annualized dividend and a dividend yield of 2.78%. Merck & Co., Inc.’s dividend payout ratio is currently 48.24%.

In other news, EVP Adam H. Schechter sold 134,094 shares of Merck & Co., Inc. stock in a transaction dated Monday, June 18th. The stock was sold at an average price of $61.00, for a total value of $8,179,734.00. Following the transaction, the executive vice president now owns 100,000 shares in the company, valued at $6,100,000. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Rita A. Karachun sold 5,000 shares of Merck & Co., Inc. stock in a transaction dated Thursday, August 2nd. The stock was sold at an average price of $65.01, for a total value of $325,050.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 396,393 shares of company stock worth $25,235,061. Company insiders own 0.32% of the company’s stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Featured Article: What is the NASDAQ?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.